ID: pemafibrate
Aliases: Parmodia
Type: compound
Route/form: oral or route depends on studied product
Status: approved_in_some_countries
Evidence level: human RCT
Best data tier: human controlled/review
Support scope: human
Source types: human_rct, human_rct_negative
Linked sources: 2
Broad outcomes: Cardiovascular / lipids / blood pressure, Fat loss / metabolic health, Gut / immune / inflammation
Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.
Targets / mechanism
- selective PPAR-alpha modulator
Optimization domains
- triglycerides
- cardiometabolic
- liver
Research basis
- Pemafibrate is a potent selective PPAR-alpha modulator with human RCT evidence for triglyceride lowering.
- It is an important reality check for PPAR enthusiasm because lipid-marker improvement did not translate into lower cardiovascular events in PROMINENT.
- The most defensible repository role is lipid/metabolic pharmacology context, not broad longevity or body-composition benefit.
Limits, risks, and missing evidence
- PROMINENT is a negative cardiovascular-outcomes anchor despite triglyceride lowering.
- Liver, gallbladder, renal, muscle, and drug-interaction monitoring may matter depending on context.
- PPAR target activation should not be treated as a generic optimization signal without outcome data.
Risk flags
- approved or regional drug
- ppar alpha
- negative outcome trial
- lipid marker vs outcome gap
Linked papers, labels, and reviews
- Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
human_rct_negative / pubmed_pemafibrate_prominent_2022
PROMINENT outcomes trial; important direct negative/neutral evidence separating triglyceride lowering from cardiovascular event reduction. - Efficacy and safety of K-877 pemafibrate in European patients on statin therapy
human_rct / pubmed_pemafibrate_phase2_europe_2022
Phase 2 randomized trial showing triglyceride lowering on top of statin therapy; contrasts with negative PROMINENT outcomes.